Abstract
Quantitative competitive PCR was used to monitor the quantity of cytomegalovirus (HCMV) in 1647 blood samples from 110 BMT recipients. DNAemia was detected in 49/110 (45%) of the patients, of whom 15/49 experienced HCMV disease. Peak virus load during surveillance was elevated in symptomatic (median 4.5 log10 genomes/ml) vs asymptomatic patients (median 3.6 log10 genomes/ml, P = 0.002) and was also significantly elevated in HCMV seropositive recipients of seronegative marrow, (R+D−, median 5.0 log10), compared to those in the R−D− and R+D+ groups (P < 0.01 and <0.005). odds ratios for disease per 0.25 log10 increase in viral load, recipient seropositivity and aGVHD were 1.43 (P = 0.004), 6.60 (P = 0.05) and 3.17 (P = 0.08), respectively. In multivariate logistic regression analysis only elevated viral load remained a significant risk factor for HCMV disease. The computed disease probability viral load curve showed a rapid increase in disease risk at viral loads between 3.8 and 5.5 log10 genomes/ml in blood, and odds ratios for disease were determined for different threshold viral loads. These data demonstrate the central role of viral load in the pathogenesis of HCMV in BMT recipients and provide an additional marker for targeting and monitoring therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gor, D., Sabin, C., Prentice, H. et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 21, 597–605 (1998). https://doi.org/10.1038/sj.bmt.1701139
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701139
Keywords
This article is cited by
-
Risk factors for cytomegalovirus reactivation in patients with kidney disease under immunosuppressive therapy
Clinical and Experimental Nephrology (2022)
-
Ruxolitinib–ECP combination treatment for refractory severe chronic graft-versus-host disease
Bone Marrow Transplantation (2021)
-
Pathogenesis of human cytomegalovirus in the immunocompromised host
Nature Reviews Microbiology (2021)
-
Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT
Annals of Hematology (2020)
-
Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): a systematic review
Advances in Rheumatology (2019)